A Multicentre, Open-label, Extension Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy

Trial Profile

A Multicentre, Open-label, Extension Study in Children With Inadequately Controlled Partial Onset Seizures to Investigate Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) as Adjunctive Therapy

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs Oxcarbazepine (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Nobelpharma; Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2018 Planned End Date changed from 20 Dec 2017 to 29 Mar 2019.
    • 05 Jun 2018 Planned primary completion date changed from 20 Dec 2017 to 29 Mar 2019.
    • 20 Apr 2017 Planned End Date changed from 1 Feb 2017 to 20 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top